Email this article The thymidine kinase-1 as a potential tumor marker: structure, function, activity in normal and malignant tissues
- Authors: Sergeeva N.S.1, Parilova N.K.2, Marshutina N.V.2, Meysner I.S.3
-
Affiliations:
- P.A. Hertzen Moscow Oncology Research Institute – branch of the National Medical Research Radiological Center, Ministry of Health of Russia N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia
- P.A. Hertzen Moscow Oncology Research Institute – branch of the National Medical Research Radiological Center, Ministry of Health of Russia
- N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia
- Issue: Vol 4, No 1 (2017)
- Pages: 17-23
- Section: REVIEW ARTICLES
- Published: 18.04.2017
- URL: https://umo.abvpress.ru/jour/article/view/83
- DOI: https://doi.org/10.17650/2313-805X-2017-4-1-17-23
- ID: 83
Cite item
Full Text
Abstract
In the review the role of the thymidine kinase (TK) to ensure the replication of DNA de novo and spare (salvage the) way in health and activate alternate ways in carcinogenesis is described. The structure of cytoplasmic TK (TК-1), also called fetal, and the level of regulation of its activity in the cells and their change during the cell cycle is described. Considering the data about the absence of TK-1 in resting (G0) cells, TK-1 is positioned as a marker of proliferating cells, which activity is recorded from late G1 phase, peaking in S-phase, it is stored in the G2 and mitosis, quickly decreasing to undetectable levels in the early G1 phase. Data on the expression TK-1 (as compared with Ki-67 and PCNA (proliferating cell nuclear antigen)) in tumor tissues (colorectal, breast, cervical, lung, renal, prostate and ovarian cancer), as well as some benign and precancerous pathological processes in relation to the clinical and diagnostic features of these processes are systemized. These data suggest that the proliferative index studies on TK-1 (antibody to the domain HRA-210) should be used together with Ki-67 and PCNA, for a more complete assessment of the proliferative status of malignant tumors and pre-cancerous and benign conditions, with the aim of prognosis of the tumor process and treatment planning.
Keywords
About the authors
N. S. Sergeeva
P.A. Hertzen Moscow Oncology Research Institute – branch of the National Medical Research Radiological Center, Ministry of Health of RussiaN.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia
Author for correspondence.
Email: prognoz.06@mail.ru
Department of Conservative Treatment Prognosis
3 2nd Botkinskiy Proezd, Moscow 125284, Russia
1 Ostrovityanovа St., Moscow 117997, Russia
Russian FederationN. K. Parilova
P.A. Hertzen Moscow Oncology Research Institute – branch of the National Medical Research Radiological Center, Ministry of Health of Russia
Email: fake@neicon.ru
Department of Conservative Treatment Prognosis
3 2nd Botkinskiy Proezd, Moscow 125284, Russia
Russian FederationN. V. Marshutina
P.A. Hertzen Moscow Oncology Research Institute – branch of the National Medical Research Radiological Center, Ministry of Health of Russia
Email: fake@neicon.ru
Department of Conservative Treatment Prognosis
3 2nd Botkinskiy Proezd, Moscow 125284, Russia
Russian FederationI. S. Meysner
N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia
Email: fake@neicon.ru
1 Ostrovityanovа St., Moscow 117997, Russia Russian Federation
References
Supplementary files
